Statement: in the primary clinical trial, one adverse event alone impacted 200 patients.
Primary_evidence: Adverse Events 1:   Total: 340/1612 (21.09%)   Anemia 10/1612 (0.62%)   Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%)   Febrile neutropenia 7/1612 (0.43%)   Cardiac disorders - Other, specify 6/1612 (0.37%)   Conduction disorder 2/1612 (0.12%)   Myocardial infarction 6/1612 (0.37%)   Palpitations 1/1612 (0.06%)   Pericardial effusion 0/1612 (0.00%)   Sinus bradycardia 2/1612 (0.12%) Adverse Events 2:   Total: 350/1623 (21.57%)   Anemia 8/1623 (0.49%)   Blood and lymphatic system disorders - Other, specify 3/1623 (0.18%)   Febrile neutropenia 4/1623 (0.25%)   Cardiac disorders - Other, specify 2/1623 (0.12%)   Conduction disorder 1/1623 (0.06%)   Myocardial infarction 4/1623 (0.25%)   Palpitations 0/1623 (0.00%)   Pericardial effusion 2/1623 (0.12%)   Sinus bradycardia 0/1623 (0.00%)